[Federal Register Volume 79, Number 178 (Monday, September 15, 2014)]
[Notices]
[Pages 54987-54989]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-21856]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the U.S. patent applications listed below may be obtained by writing to 
the indicated licensing contact at the Office of Technology Transfer, 
National Institutes of Health, 6011 Executive Boulevard, Suite 325, 
Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-
0220. A signed Confidential Disclosure Agreement will be required to 
receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: Technology descriptions follow.

A Novel Fusion Protein for Inhibiting HIV Budding

    Description of Technology: Ubiquitin plays a critical role in HIV-1 
budding. Vectors containing deubiquitin enzymes (DUbs) were constructed 
to deliver DUbs to HIV-1 production sites in living cells. The DUbs 
vectors comprise DUb cDNAs and cDNA expressing either HIV-1 gag, or the 
ESCRT protein TSG101.

[[Page 54988]]

    Experimental data show that the fusion proteins expressed by the 
DUbs vectors retained their known protein-protein interactions and 
caused a significant and specific interruption of HIV-1 budding. The 
data suggest that the DUbs vectors could be used to inhibit HIV-1 
infection or propagation in an individual. Thus, the DUbs vectors could 
potentially be used in high-risk individuals to prevent HIV-1 infection 
or as an adjunct therapy with known Anti-Retroviral Therapy (ART/HAART) 
in infected individuals.
    Potential Commercial Applications:

 Prevention for HIV
 Treatment for patients infected with HIV
 Clinical research

    Competitive Advantages:

 Use for both treatment and prevention
 No development of resistance to HIV
    Development Stage: In vitro data available.
    Inventors: Fadila Bouamr and Paola Sette (NIAID).
    Publication: Sette P, et al. Ubiquitin conjugation to Gag is 
essential for ESCRT-mediated HIV-1 budding. Retrovirology. 2013 Jul 
29;10:79 [PMID 23895345].
    Intellectual Property: HHS Reference No. E-223-2014/0--U.S. 
Provisional Application No. 62/030,193 filed 29 July 2014.
    Licensing Contact: John Stansberry, Ph.D.; 301-435-5236; 
[email protected].
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is seeking statements of capability or 
interest from parties interested in collaborative research to further 
develop, evaluate or commercialize the DUbs vectors and/or the fusion 
proteins expressed by the vectors. For collaboration opportunities, 
please contact Fadilla Bouamr, Ph.D. at [email protected].

Surgical Tool for Subretinal Tissue Implantation

    Description of Technology: The invention pertains to a surgical 
tool for implanting a sheet of tissue into the eye in such a way that 
damage to the tissue and the eye during insertion and manipulation of 
the tissue is minimized. The device enables tissue to be released and 
delivered in a precise and controlled fashion. The device includes a 
hollow handle portion (e.g. a syringe) with a bore fashioned to convey 
fluid. An injector is fluidically coupled to the handle of the device 
and includes a flat triangular shaped tip that defines an aperture 
connected to the internal channel of the injector portion and 
configured to enshroud a tissue for transplantation. Vacuum or pressure 
of a hydrostatic pump impels the fluid and enshrouded tissue into the 
tool and then into the eye. The tip of the surgical injector tool 
curved in a direction extending distally away from a handle of the 
surgical injector tool to better accommodate eye curvature.
    Potential Commercial Applications:

 Ocular tissue transplantation
 Subretinal tissue transplantation
 Delivery of extended release drug pellets into subretinal 
space
 Ocular surgery
 Endothelial keratoplasty

    Competitive Advantages:

 Precision of operation for surgeon (no extra moving parts)
 Instrument consists of separate disposable parts
 Controlled delivery
 Minimization of damage to the eye and transplanted tissue
 Ease of operation
 There is no available instrument capable to deliver tissue 
into subretinal space

    Development Stage:

 Early-stage
 In vivo data available (animal)
 Prototype

    Inventor: Arvydas Maminishkis (NEI).

    Intellectual Property: HHS Reference No. E-192-2014/0--U.S. 
Provisional Application No. 62/023,289 filed 11 July 2014.
    Licensing Contact: Michael Shmilovich, Esq., CLP; 301-435-5019; 
[email protected]
    Collaborative Research Opportunity: The National Eye Institute is 
seeking statements of capability or interest from parties interested in 
collaborative research to further develop, evaluate or commercialize 
ocular tissue transplantation device. For collaboration opportunities, 
please contact Matthew McMahon at 301-451-1610 or 
[email protected].

A Novel Demodulation System in X-ray Imaging

    Description of Technology: In various x-ray imaging methods, 
including scattering correction and phase contrast imaging, intensity 
modulation in space is introduced into the projection images by the use 
of masks, gratings, or apertures. The present invention relates to a 
process to demodulate the modulation. The current demodulation 
processes are either to remove the modulation pattern through digital 
processing or to move the modulation pattern on the detector in a 
series of images that requires mechanical movements of a component and 
tends to lose some information of the imaged object. The demodulation 
of the present invention can be realized with a relative movement 
between the projected image of the sample and the modulation pattern 
without having to move the modulation pattern. The demodulated images 
are free of the modulation pattern and have better clarity.
    Potential Commercial Applications:

 Clinical diagnostic
 Research tools
 Security inspections

    Competitive Advantages:

 Better clarity for images
 Simplify the demodulation method

    Development Stage:

 In vitro data available
 In vivo data available (animal)

    Inventors: Han Wen and Houxun Miao (NHLBI)
    Publications:
    1. David C, et al. Interferometer for quantitative phase contrast 
imaging and tomography with an incoherent polychromatic x-ray source. 
U.S. Patent No. 7,889,838 issued 15 Feb 2011. [http://patft1.uspto.gov/netacgi/nph-Parser?patentnumber=7889838].
    2. Schusser S, Vogtmeier G. Non-parallel grating arrangement with 
on-the-fly phase stepping, x-ray system and use. PCT Application No. 
PCT/IB2010/055562 filed 02 Dec 2010. [http://patentscope.wipo.int/search/en/WO2011070489].
    Intellectual Property: HHS Reference No. E-113-2013/0--U.S. 
Provisional Application No. 61/877,219 filed 12 Sep 2013.
    Licensing Contact: John Stansberry, Ph.D.; 301-435-5236; 
[email protected].
    Collaborative Research Opportunity: The National Heart, Lung, and 
Blood Institute is seeking statements of capability or interest from 
parties interested in collaborative research to further develop, 
evaluate or commercialize the technology. For collaboration 
opportunities, please contact Dr. Denise Crooks at 
[email protected].

A Novel X-ray Grating To Enhance Phase Contrast Imaging

    Description of Technology: The present invention relates to 
improving x-ray phase contrast imaging. The invention discloses a novel 
grating interferometer for phase contrast imaging with hard x-rays that 
overcomes limitations in the level of sensitivity by utilizing the 
advantages of far-field interferometers. The novel design and 
fabrication process can easily acquire absolute and differential

[[Page 54989]]

phase images of lightly absorbing samples.
    Potential Commercial Applications:

 Clinical diagnostics
 Research tools

    Competitive Advantages:

 More sensitivity
 Easier to fabricate images

    Development Stage:

 In vitro data available
 In vivo data available (animal)

    Inventor: Han Wen (NHLBI)
    Publications:
    1. Wen H. Boosting phase contrast with two-arm interferometers 
using sub-micron period gratings. Presentation, The Royal Society, 
London scientific discussion meeting: Taking x-ray phase contrast 
imaging into mainstream applications, February 11, 2013, London, UK.
    2. Momose A, Fukuda J. Phase-contrast radiographs of nonstained rat 
cerebellar specimen. Med Phys. 1995 Apr;22(4):375-9. [PMID 7609717].
    3. Clauser JF. Ultrahigh resolution interferometric x-ray imaging. 
U.S. Patent No. 5,812,629 issued 22 Sep 1998. [http://patft1.uspto.gov/netacgi/nph-Parser?patentnumber=5812629].
    Intellectual Property: HHS Reference No. E-114-2013/0--U.S. 
Provisional Application No. 61/877,228 filed 12 Sep 2013.
    Licensing Contact: John Stansberry, Ph.D.; 301-435-5236; 
[email protected].
    Collaborative Research Opportunity: The National Heart, Lung, and 
Blood Institute is seeking statements of capability or interest from 
parties interested in collaborative research to further develop, 
evaluate or commercialize the technology. For collaboration 
opportunities, please contact Dr. Denise Crooks at 
[email protected].

    Dated: September 9, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 2014-21856 Filed 9-12-14; 8:45 am]
BILLING CODE 4140-01-P